论文部分内容阅读
重金属复合顺铂(Cis DDP)已被公认为治疗睾丸、卵巢、头颈部癌的有效抗肿瘤药,但它具有耳毒性,最近报道该药引起听力减退的发生率为25～91%。本文报告用Cis DDP作为多种药物联合治疗的一部分治疗头颈部癌50例的测听资料分析,并用豚鼠造模研究应用不同浓度的Cis-DDP和高累积量的耳蜗形态学改变。头颈部癌患者应用Cis DDP、氨甲喋呤及博来霉素联合治疗1～3疗程,间隔3周。其中38例3疗程,7例2疗程,5例1疗程。Cis DDP静脉注射量为60mg m~2体表面积;同时采取预防肾毒性的措施。测听是分别在首次疗程前、后,第二疗程前、后及末次用Cis DDP2～5周时进行。动物造模用6只4月龄雌性豚鼠,等分为两
Cis DDP has been recognized as an effective antineoplastic agent for the treatment of testicular, ovarian, head and neck cancers, but it has ototoxicity and the recent reported incidence of hearing loss is 25-91%. This article reports the audiometric analysis of 50 patients with head and neck cancer treated with Cis DDP as part of a multidrug combination regimen. Cis-DDP at different concentrations and high cumulative amounts of cochlear morphological changes were studied using guinea pig modeling. Head and neck cancer patients with Cis DDP, methotrexate and bleomycin combination treatment of 1 to 3 courses, at an interval of 3 weeks. 38 cases of 3 courses, 7 cases of 2 courses, 5 cases of a course of treatment. Cis DDP intravenous injection of 60mg m ~ 2 body surface area; at the same time to take measures to prevent nephrotoxicity. Audiometry was performed before and after the first course of treatment, before and after the second course of treatment and at the end of the second course of treatment with Cis DDP for 2 to 5 weeks. Animal modeling Six 6-month old female guinea pigs were equally divided into two